AlphaQuest LLC Boosts Stock Holdings in CVRx, Inc. $CVRX

AlphaQuest LLC grew its position in CVRx, Inc. (NASDAQ:CVRX) by 114.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,106 shares of the company’s stock after purchasing an additional 6,998 shares during the period. AlphaQuest LLC owned about 0.05% of CVRx worth $77,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in CVRX. Parkman Healthcare Partners LLC grew its position in CVRx by 33.5% in the 1st quarter. Parkman Healthcare Partners LLC now owns 1,229,522 shares of the company’s stock worth $15,037,000 after purchasing an additional 308,348 shares in the last quarter. Lord Abbett & CO. LLC purchased a new position in shares of CVRx in the 1st quarter worth approximately $4,852,000. Russell Investments Group Ltd. grew its holdings in shares of CVRx by 70.1% in the first quarter. Russell Investments Group Ltd. now owns 61,133 shares of the company’s stock valued at $748,000 after acquiring an additional 25,194 shares in the last quarter. Principal Financial Group Inc. purchased a new stake in shares of CVRx during the first quarter valued at approximately $731,000. Finally, Cubist Systematic Strategies LLC lifted its holdings in CVRx by 48.1% during the first quarter. Cubist Systematic Strategies LLC now owns 59,105 shares of the company’s stock worth $723,000 after acquiring an additional 19,183 shares during the period. 75.27% of the stock is owned by institutional investors.

CVRx Trading Down 2.0%

Shares of CVRx stock opened at $9.79 on Thursday. The company has a debt-to-equity ratio of 0.85, a current ratio of 11.99 and a quick ratio of 10.78. CVRx, Inc. has a 1 year low of $4.30 and a 1 year high of $18.55. The firm has a market cap of $256.03 million, a PE ratio of -4.66 and a beta of 1.28. The company has a 50 day simple moving average of $8.66 and a two-hundred day simple moving average of $7.51.

CVRx (NASDAQ:CVRX) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.01. CVRx had a negative net margin of 95.61% and a negative return on equity of 79.31%. The firm had revenue of $14.69 million for the quarter, compared to analysts’ expectations of $14.16 million. CVRx has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS. Analysts expect that CVRx, Inc. will post -1.91 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have issued reports on CVRX. Weiss Ratings restated a “sell (e+)” rating on shares of CVRx in a research note on Thursday, October 30th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $11.00 price target on shares of CVRx in a research report on Tuesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat, CVRx has an average rating of “Moderate Buy” and a consensus target price of $14.00.

CVRx Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.